New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2013
11:43 EDTNVS, BAYRY, ACTAppeals court reverses ruling in Actavis patent suit against Bayer
Watson Pharmaceuticals, now known as Actavis (ACT), along with Novartis' (NVS) Sandoz, unit and Lupin Pharmaceuticals, appealed the final judgments of the United States District Court for the District of Nevada in favor of Bayer Healthcare Pharmaceuticals and Bayer Schering Pharma (BAYRY). The Defendants challenged the district court’s entry of summary judgment that asserted claims 13 and 15 of Bayer’s U.S. "’564 patent” are not invalid for obviousness. The appeals court ruled in favor of the generic drug makers and reversed the lower court ruling. Reference Link
News For ACT;BAYRY;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
05:25 EDTBAYRYRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
14:01 EDTBAYRYBayer initiated with a Buy at HSBC
Subscribe for More Information
08:00 EDTBAYRYBayer to hold a meeting
Subscribe for More Information
June 23, 2015
10:31 EDTBAYRYMonsanto says Bayer crop chemicals unit an option, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use